Clinical Trial Update: Safinamide for Levodopa-induced Dyskinesia (PD-LID) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial for safinamide in Parkinson disease with levodopa-induced dyskinesia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesia Drug-induced
• Parkinson Disease

Drugs mentioned

• Safinamide (Safinamide)

Snippet

Sponsor: Zambon SpA | Conditions: Dyskinesia, Drug-Induced, Parkinson Disease | Phase 3 | Status: WITHDRAWN